Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.57 |
| ▸ | CRHBP | P24387 | 2/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.56 |
| ▸ | G6PD | P11413 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3208528 | 0.82 | HPGD (0.66) | HPGDSMN1; SMN2KDM4EHTTALDH1A1 | |
| SCHEMBL16840300 | 0.77 | HPGD (0.69) | HPGDSMN1; SMN2HTTALDH1A1GAA | |
| SCHEMBL6005231 | 0.76 | HPGD (0.66) | HPGDPTPN1SMN1; SMN2KDM4EHTT | |
| SCHEMBL27504229 | 0.75 | RAB9A (0.67) | CRHBPCRHR2G6PDSMN1; SMN2ALDH1A1 | |
| SCHEMBL3213334 | 0.75 | HPGD (0.50) | HPGDSMN1; SMN2KDM4EHTTALDH1A1 | |
| SCHEMBL3198208 | 0.75 | POLB (0.57) | HPGDCRHBPCRHR2G6PDSMN1; SMN2 | |
| SCHEMBL7159826 | 0.75 | MEN1 (0.60) | HPGDCRHBPCRHR2G6PDSMN1; SMN2 | |
| SCHEMBL12260755 | 0.74 | CRHBP (0.62) | HPGDCRHBPCRHR2G6PDSMN1; SMN2 | |
| SCHEMBL7160222 | 0.74 | HPGD (0.62) | HPGDCRHBPCRHR2HTTALDH1A1 | |
| SCHEMBL7162767 | 0.74 | CRHBP (0.73) | CRHBPCRHR2G6PDSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235908-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists | SCHERING CORPORATION | 2004-11-25 | — | — | US | disclosed |
| US-20030204085-A1 | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists | PHARMACOPEIA, INC. | 2003-10-30 | — | — | US | disclosed |
| EP-1355875-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC CHEMOKINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030097004-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists | SCHERING CORPORATION | 2003-05-22 | — | — | US | disclosed |
| WO-2002076926-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC CHEMOKINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235908-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists | CCR1, CXCR1, ACKR3 | HPGD 154/4885CRHBP 289/4885CRHR2 124/4885 |
| US-20030097004-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists | CCR1, ACKR3, CXCR1 | HPGD 123/4885CRHBP 326/4885CRHR2 104/4885 |
| US-20030204085-A1 | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists | CCR1, CXCR1, ACKR3 | HPGD 154/4885CRHBP 289/4885CRHR2 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.